Fasciculation

WiMi Releases A Highly Reliable Silent Speech Recognition System Based on Multi-featured Signal Sensing Technology

Retrieved on: 
Tuesday, April 25, 2023

BEIJING, April 25, 2023 /PRNewswire/––WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today disclosed a highly reliable silent speech recognition system based on multi-featured signal perception technology.

Key Points: 
  • BEIJING, April 25, 2023 /PRNewswire/––WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today disclosed a highly reliable silent speech recognition system based on multi-featured signal perception technology.
  • The system can convert electrical signals from body or laryngeal vocal cord movements into speech through silent reading or body movement recognition.
  • Therefore, WiMi developed this system to enable silent speech recognition by using limb movements or facial electromyography in a holographic AR environment.
  • WiMi expects that this system will contribute to the further development of speech recognition technology and provide new ideas and methods for speech recognition.

Landmark Study Finds Pison AI Technology Can Detect Neurological Disorder in ALS Patients

Retrieved on: 
Tuesday, April 18, 2023

These results demonstrate that Pison’s technology has the potential to become a digital biomarker to detect neurological diseases, monitor progression, and inform treatment.

Key Points: 
  • These results demonstrate that Pison’s technology has the potential to become a digital biomarker to detect neurological diseases, monitor progression, and inform treatment.
  • The study found that Pison’s technology could distinguish between patients diagnosed with ALS and a healthy population.
  • The technology demonstrated that it could detect fasciculations and differentiation between healthy people and people living with ALS in a resting state using deep learning algorithms.
  • “This clinical result is an important step towards receiving regulatory approval for medical applications of Pison technology.

Sevāredent Sourcing Solutions and Pacira BioSciences Collaborate to Provide Expanded Access to EXPAREL for Patients Undergoing Oral and Maxillofacial Procedures

Retrieved on: 
Tuesday, September 27, 2022

The patient experience, and particularly the recovery process, is paramount for individuals undergoing oral surgery procedures.

Key Points: 
  • The patient experience, and particularly the recovery process, is paramount for individuals undergoing oral surgery procedures.
  • Many patients express concerns about both postsurgical pain and opioid exposure, said Blake Hibray, Sevredent President.
  • EXPAREL has been studied across a wide variety of oral and maxillofacial procedures including full arch implant, third molar extraction and soft palate surgeries.
  • We are thrilled to partner with Sevredent to increase access to providers and patients alike.

Global Citric Acid Market Outlook to 2027 - Featuring Cargill, Tate & Lyle and Kenko Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, April 8, 2022

According to the publisher, the global Citric Acid market is expected to witness a significant growth rate during the forecasted period.

Key Points: 
  • According to the publisher, the global Citric Acid market is expected to witness a significant growth rate during the forecasted period.
  • Factors like increasing the use of Citric Acid in the food industry, Citric Acid aids in the preservation of canned and jar goods over extended periods are expected to drive the global Citric Acids market.
  • Further, Citric Acid is mainly used as an exfoliator in the personal care industry, and antioxidants in skincare products are projected to drive the Global Citric Acids Market.
  • Citric Acid's acidic pH makes it beneficial as a food preservative and helps retain the color of food by significantly slowing oxidation, driving the Global Citric Acids market.

Amyotrophic Lateral Sclerosis (ALS) Market Spotlight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022

The "Market Spotlight: Amyotrophic Lateral Sclerosis (ALS)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Amyotrophic Lateral Sclerosis (ALS)" report has been added to ResearchAndMarkets.com's offering.
  • Amyotrophic lateral sclerosis (ALS) is a fatal late-onset neurodegenerative disorder characterized by progressive muscular paralysis.
  • Common symptoms reported by patients with ALS include muscle twitching, weakness, and cramping, which subsequently lead to muscle impairment.
  • The publisher estimates that in 2019, there were 28,100 incident cases of amyotrophic lateral sclerosis (ALS) in adults aged 40 years and older worldwide, and forecasts that number to increase to 32,600 incident cases by 2028.

Pacira BioSciences Reports Preliminary Net Product Sales of $44.3 Million for October 2021

Retrieved on: 
Tuesday, November 9, 2021

TAMPA, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales.

Key Points: 
  • TAMPA, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales.
  • EXPAREL (bupivacaine liposome injectable suspension) net product sales of $42.5 million for the month of October 2021, compared with $40.7 million for the prior year.
  • Net product sales of iovera were $1.2 million for the month of October 2021, compared with $1.0 million for the prior year.
  • To provide greater transparency, the company is reporting monthly intra-quarter unaudited net product sales until it has gained enough visibility around the impacts of COVID-19.

Pacira Receives Notice of Allowance for New Patent Covering EXPAREL Composition

Retrieved on: 
Tuesday, November 2, 2021

TAMPA, Fla., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a U.S. Patent Application claiming chemical composition of EXPAREL® (bupivacaine liposome injectable suspension). After issuance, Pacira will submit this patent for listing in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book). Patents that are eligible for Orange Book listing are those that have claims covering the active ingredient, the drug product (formulation and composition) or the approved method of use.

Key Points: 
  • The company also received a Notice of Allowance from the USPTO for a separate patent application claiming a novel EXPAREL manufacturing process.
  • A Notice of Allowance is issued after the USPTO concludes a substantive examination of the patent application and determines that the prosecution on the merits of a patent has been completed.
  • The composition patent and the manufacturing process patent will each have an expiration date of January 22, 2041.
  • We are pleased to enhance our intellectual property protection for EXPAREL with two new patents, including another Orange Book eligible product composition patent, said Dave Stack, chairman and chief executive officer of Pacira BioSciences.

Pacira BioSciences Notified of Abbreviated New Drug Application Filing for EXPAREL®

Retrieved on: 
Monday, October 4, 2021

These new patents will establish multiple layers of patent protection and extend the companys proprietary position for EXPAREL into the 2040s.

Key Points: 
  • These new patents will establish multiple layers of patent protection and extend the companys proprietary position for EXPAREL into the 2040s.
  • Pacira intends to vigorously defend its intellectual property rights relating to EXPAREL.
  • Pacira BioSciences, Inc. (Nasdaq: PCRX) is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients journeys along the neural pain pathway.
  • The companys long-acting local analgesic, EXPAREL (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012.

Pacira Announces Commercial Production Underway with Enhanced EXPAREL Manufacturing Process at Swindon Facility

Retrieved on: 
Thursday, September 30, 2021

Pacira expects to begin selling commercial product manufactured in the 200-liter suite before the end of 2021.

Key Points: 
  • Pacira expects to begin selling commercial product manufactured in the 200-liter suite before the end of 2021.
  • Importantly, this enhanced process has allowed us to add another layer of market exclusivity for EXPAREL through the issuance of a new Orange Book-listed patent that extends our proprietary position to January 2041.
  • Process validation is required by FDA before any product from a new manufacturing process is commercially distributed for use by consumers to demonstrate the process will consistently produce drug product that meets predefined specifications.
  • The companys long-acting local analgesic, EXPAREL (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012.

Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries

Retrieved on: 
Tuesday, September 21, 2021

PARSIPPANY, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that full results of its Phase 3 PLAY study of EXPAREL (bupivacaine liposome injectable suspension) administered via infiltration in pediatric patients undergoing spinal or cardiac surgeries have been published in Journal of Clinical Anesthesia .

Key Points: 
  • PARSIPPANY, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that full results of its Phase 3 PLAY study of EXPAREL (bupivacaine liposome injectable suspension) administered via infiltration in pediatric patients undergoing spinal or cardiac surgeries have been published in Journal of Clinical Anesthesia .
  • There were no treatment-related cardiac or nervous system adverse events (AEs) in the EXPAREL arm.
  • Additionally, AEs were mild to moderate, supporting the safety of EXPAREL in pediatric patients undergoing spine or cardiac surgery.
  • Results of this study build upon a growing body of evidence supporting the use of EXPAREL in pediatric procedures.